Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy

Conclusions: EP and EPclin were highly prognostic for DR in endocrine-treated patients with ER+, HER2-negative disease. EPclin provided more prognostic information than RS. This was partly but not entirely because of EPclin integrating molecular data with nodal status and tumor size.

Source: JNCI - July 9, 2016 Category: Cancer & Oncology Authors: Buus, R., Sestak, I., Kronenwett, R., Denkert, C., Dubsky, P., Krappmann, K., Scheer, M., Petry, C., Cuzick, J., Dowsett, M. Tags: Article Source Type: research